中轴型脊柱关节炎患者TNF抑制剂原发无效:25例长期随访
该回顾性研究在一个三级转诊中心评估222例首次接受TNF抑制剂(TNFi)治疗的中轴型脊柱关节炎(axSpA)患者,其中27例(12%)被判定为原发无效。5至10年后对25例进行再评估,21/25(84%)仍符合axSpA诊断,但18/25(72%)至少存在一种其他疼痛原因(骨关节炎、广泛性疼痛综合征或抑郁)。16例换用第二种TNFi,其中9例(56%)有效。
要点
- axSpA患者TNFi原发无效并不罕见,本队列中占12%。
- 原发无效者中多数仍确诊axSpA,但常合并其他疼痛原因。
- 换用第二种TNFi后约56%的患者有效。
核心结论
- 多数TNFi原发无效的axSpA患者诊断仍可确认,但常合并其他疼痛原因。
- 建议对TNFi原发无效者筛查可能干扰axSpA活动度评估的合并症。
研究设计与样本
- 单中心系统性回顾性研究,纳入222例首次接受TNFi治疗的axSpA患者。
- 原发无效定义为风湿科医生因无效在3个月时中断治疗,5至10年后对25例进行再评估。
主要发现
- 222例中27例(12%)被判定为TNFi原发无效。
- 原发无效者女性更多(48% vs 27%,P=0.04),BASDAI(0-100)更高(68 vs 42,P=0.001),CRP升高者更少(50% vs 78%,P=0.008)。
- 再评估的25例中,按ASAS标准21/25(84%)确诊axSpA,按风湿科医生判断20/25(80%)确诊。
- 18/25(72%)至少存在一种其他疼痛原因,包括骨关节炎、广泛性疼痛综合征或抑郁。
- 16例换用第二种TNFi,其中9例(56%)有效。
关键数值与推荐
- 原发无效定义:风湿科医生因无效在3个月时中断TNFi治疗。
- axSpA诊断确认依据ASAS标准或风湿科医生判断。
临床怎么用
- 对TNFi原发无效的axSpA患者,应筛查骨关节炎、广泛性疼痛综合征和抑郁等合并症。
- 合并症可能干扰axSpA活动度评估,需在换药前综合考虑。
局限性
- 单中心回顾性研究,样本量小(再评估25例)。
- 原文未报告随访时长、失访原因等细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Primary inefficacy of TNF inhibitors (TNFi) for axial spondyloarthritis (axSpA) is infrequent. The objective of this study was to assess the long-term evolution and final diagnosis of patients with primary inefficacy of TNFi for axSpA. METHODS: This was a systematic retrospective study of all patients receiving a TNFi for axSpA in one tertiary referral centre. Patients had axSpA confirmed by a rheumatologist and were started on a first course of TNFi according to usual practice. If the rheumatologist interrupted treatment at 3 months for inefficacy, this was defined as primary inefficacy. Five to 10 years later, these patients were re-evaluated. RESULTS: Of 222 patients receiving a first TNFi for axSpA, 27 (12%) were considered as having primary inefficacy. These patients were more often females (48 vs 27%, P = 0.04), had higher functional impairment [BASDAI (0-100) 68 vs 42, P = 0.001] and less increased CRP (50 vs 78%, P = 0.008.) At the follow-up, 25 (92%) patients were re-evaluated: the diagnosis of axSpA was confirmed for 21/25 (84%) patients according to the Assessment of SpondyloArthritis criteria and 20/25 (80%) patients according to the rheumatologist; but 18/25 (72%) had at least one other cause of their symptoms from among OA, widespread pain syndrome or depression. A second TNFi was prescribed for 16 patients and was efficacious for 9 (56%). CONCLUSION: Most patients with primary inefficacy had a confirmed diagnosis of axSpA, but they often had other causes of pain. We suggest that patients with primary inefficacy to TNFi should be screened for comorbidities that may interfere with axSpA activity assessment.
引用
- Kossi S, Dadoun S, Geri G, et al. Primary inefficacy of TNF inhibitors in patients with axial spondyloarthritis: a long-term follow-up of 25 patients. Rheumatology (Oxford). 2017. PMID: 28073957. doi:10.1093/rheumatology/kew456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。